Physicians' Academy for Cardiovascular Education

LDL: Future management

3' education - July 21, 2011

Prof. John Kastelein, Amsterdam, The Netherlands in discussion with Prof. Phil Barter on some of the new frontiers in the management of LDL cholesterol and cardiovascular disease.

Questions to be addressed in this PACE expert opinion are:
  • There is evidence mounting that our LDL target should be even more aggressive; What is new on the market?
  • What is the evidence that our LDL target should be even more aggressive: What is there in the pipeline?
  • About niacin: How much additional LDL lowering does it provide, when added to a statin?
  • When targeting LDL Cholesterol: What about ApoB as marker and target?
  • When measuring LDL Cholesterol: Does LDL particle size matter?
  • When measuring LDL Cholesterol: What about non-HDL as a simpler calculation?

View Expert Interview

More about LDL cholesterol

Recent trials have emphasized that more intensive low-density cholesterol (LDL-C) lowering results in a further reduction in cardiovascular disease risk. At present, statins are the most effective LDL-C lowering drugs. In a series of of primary and secondary prevention trials investigating various statins it was consistently shown that reduction in LDL-C were associated with a clear decrease in cardiovascular event rates. In this section updates and educational resources are provided on current and future strategies targeted to lower LDL cholesterol. Read more

View the Powerpoint slides presented

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: